Back to Authors

Melnik, Marianne

Mayo Clinic

Michigan Cancer Research Consortium

Citations 2

Health‐related quality of life outcomes for the LEAP study—CALGB 70305 (Alliance): A lymphedema prevention intervention trial for newly diagnosed breast cancer patients
Naughton, Michelle J. , Liu, Heshan , Seisler, Drew K., Le‐Rademacher, Jennifer , Armer, Jane M. , Oliveri, Jill M. , Sloan, Jeffrey A., Hock, Karen , Schwartz, Michael , Unzeitig, Gary, Melnik, Marianne, Yee, Lisa D., Loprinzi, Charles L. , Loprinzi, Charles , Paskett, Electra D , Le-Rademacher, Jennifer G , Yee, Lisa D., Fleming, Gini F. , Taylor, John R., Paskett, Electra D.

Cancer | October 20, 2020 | Volume: 127 | Issue: 2 | Pages: 300-309

10.1002/cncr.33184 Get It

Background Lymphedema is an adverse effect of breast cancer treatment that causes swelling and pain in the arm and hand. We tested 2 lymphedema prevention interventions and their impact on health‐related quality of life (HRQOL) in a group‐randomized trial at 38 cooperative group sites within the United States. Methods Patients were recruited before breast surgery. Sites were randomly assigned to education‐only (EO) lymphedema prevention or education plus exercise and physical therapy (LEAP). Lymphedema was defined as a ≥10% difference in arm volume at any time from baseline to 18 months postsurgery. HRQOL was assessed using the Functional Assessment of Cancer Therapy–Breast plus 4 lymphedema items (FACT‐B+4). Longitudinal mixed model regression analysis, adjusting for key demographic and clinical variables, examined participants' HRQOL by intervention group and lymphedema status. Results A total of 547 patients (56% LEAP) were enrolled and completed HRQOL assessments. The results revealed no differences between the interventions in preventing lymphedema ( P = .37) or HRQOL (FACT‐B+4 total score; P = .8777). At 18 months, the presence of lymphedema was associated with HRQOL at borderline significance ( P = .0825). However, African American patients reported greater lymphedema symptoms ( P = .0002) and better emotional functioning ( P = .0335) than patients of other races or ethnicities. Lower HRQOL during the intervention was associated with younger age ( P ≤ .0001), Eastern Cooperative Oncology Group performance status >0 ( P = .0002), ≥1 positive lymph nodes ( P = .0009), having no education beyond high school ( P < .0001), having undergone chemotherapy ( P = .0242), and having had only axillary node dissection or sentinel node biopsy versus both ( P = .0007). Conclusion The tested interventions did not differ in preventing lymphedema or in HRQOL outcomes. African American women reported greater HRQOL impacts due to lymphedema symptoms than women of other races or ethnicities.
A randomized study to prevent lymphedema in women treated for breast cancer: CALGB 70305 (Alliance)
Paskett, Electra D. , Le‐Rademacher, Jennifer , Oliveri, Jill M. , Liu, Heshan , Seisler, Drew K., Sloan, Jeffrey A., Armer, Jane M. , Naughton, Michelle J. , Hock, Karen , Schwartz, Michael , Unzeitig, Gary, Melnik, Marianne, Yee, Lisa D., Loprinzi, Charles L. , Loprinzi, Charles , Le-Rademacher, Jennifer G , Paskett, Electra D , Yee, Lisa D., Fleming, Gini F. , Taylor, John R.

Cancer | October 20, 2020 | Volume: 127 | Issue: 2 | Pages: 291-299

10.1002/cncr.33183 Get It

Background Lymphedema affects many women who are treated for breast cancer. We examined the effectiveness of an education‐only (EO) versus education plus sleeve compression/exercise intervention (lymphedema education and prevention [LEAP]) on lymphedema incidence and range of motion (ROM) in a group‐randomized trial across 38 cooperative group sites. Methods The treating institution was randomly assigned to either EO or LEAP by a study statistician. All patients at a treating institution participated in the same intervention (EO or LEAP) to minimize contamination bias. Participants completed surveys, arm volume measurements, and self‐reported ROM assessments before surgery and at 12 and 18 months after surgery. Lymphedema was defined as a ≥10% difference in limb volume at any time post‐surgery up to 18 months after surgery or diagnosis by a health provider. Cochran‐Mantel‐Haenszel tests were used to compare lymphedema‐free rates between groups, stratified by lymph node surgery type. Self‐reported ROM differences were compared between groups. Results A total of 554 participants (56% LEAP) were included in the analyses. At 18 months, lymphedema‐free rates were 58% (EO) versus 55% (LEAP) ( P = .37). ROM for both arms was greater in LEAP versus EO at 12 months; by 18 months, most women reported full ROM, regardless of group. In LEAP, only one‐third wore a sleeve ≥75% of the time; 50% performed lymphedema exercises at least weekly. Conclusion Lymphedema incidence did not differ by intervention group at 18 months. Poor adherence in the LEAP group may have contributed. However, physical therapy may speed recovery of ROM. Further research is needed to effectively reduce the incidence and severity of lymphedema in patients who have breast cancer.